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The development of a new technology based on patient-speciﬁc modelling for personalised healthcare in the case of atherosclerosis is
presented. Atherosclerosis is the main cause of death in the world and it has become a burden on clinical services as it manifests itself in
many diverse forms, such as coronary artery disease, cerebrovascular disease/stroke and peripheral arterial disease. It is also a
multifactorial, chronic and systemic process that lasts for a lifetime, putting enormous ﬁnancial and clinical pressure on national health
systems. In this Letter, the postulate is that the development of new technologies for healthcare using computer simulations can, in the
future, be developed as in-silico management and support systems. These new technologies will be based on predictive models (including
the integration of observations, theories and predictions across a range of temporal and spatial scales, scientiﬁc disciplines, key risk factors
and anatomical sub-systems) combined with digital patient data and visualisation tools. Although the problem is extremely complex, a
simulation workﬂow and an exemplar application of this type of technology for clinical use is presented, which is currently being
developed by a multidisciplinary team following the requirements and constraints of the Vascular Service Unit at the University College
Hospital, London.1. Introduction: Cardiovascular disease (CVD) is the main cause
of illness and premature death in the EU, accounting for
approximately 40% of deaths. CVD costs the EU over 192 billion
euros a year and is estimated to account for more than a quarter
of all disability-adjusted life years lost in the EU [1]. CVD is
forecast to remain the leading cause of disability in developed
countries for many years. Within the wide spectrum of CVD,
atherosclerosis has been singled out as the leading cause of death.
Atherosclerosis is a degenerative condition in which an artery
wall thickens as the result of a build-up of lipids (primarily choles-
terol and fatty acids) and ﬁbrosis of the wall. It is commonly re-
ferred to as a ‘hardening’ or ‘furring’ of the arteries. In the early
stages, an accumulation of lipid-laden macrophages (foam cells)
is seen in the subendothelium. With time, smooth muscle cells
and ﬁbrous tissue will accumulate. The formation of lesions is
enhanced by plasma proteins carrying elevated levels of cholesterol
and triglycerides, and also blood pressure is a driving force of ath-
erosclerosis progression.
Atherosclerosis is a chronic, progressive and multifactorial
disease with a long asymptomatic phase. Clinical manifestations
of atherosclerosis including coronary artery disease (also called ath-
erosclerotic heart disease), cerebrovascular disease and peripheral
arterial disease will occur in 2 of 3 men and 1 in 2 women after
the age of 40. Subclinical atherosclerosis is a latent precursor of
clinical CVD, including myocardial infarction and stroke [2].
According to the European Society of cardiology [1], patient out-
comes could be greatly improved if we were able to shift from treat-
ment to prevention. Now, more than ever, national health systems
must deal with the pressures facing governments trying to maintain
health provisions under ﬁscal constraints, with health funders
experiencing difﬁculties in meeting the demands of modern
health systems. Pressures arise from many quarters, including: an
ageing population needing longer and more intensive medical
treatments; population increase and patient and clinician demands
for the latest equipment/services, among others. FundamentalHealthcare Technology Letters, pp. 13–18
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Cunderstanding of the formation of atherosclerosis, cost-effective
management and cost-controlled treatment of the disease in the
long term are becoming essential. However, atherosclerosis is a
complex process and the progression of the disease will depend
on patient-speciﬁc anatomical characteristics (which inﬂuence the
mechanical stimuli on the endothelium), as well as environmental
and lifestyle factors (such as age and smoking) and genetic vari-
ables. The complicated framework that encapsulates plaque forma-
tion and the myriad of cause-effect relationships at multiple levels
make management of the condition almost intractable for clinicians
who, nevertheless, must deal with it every day. Hence, an in-silico
management and support system, based on predictive models (in-
cluding the integration of observations, theories and predictions
across a range of temporal and spatial scales, scientiﬁc disciplines,
key risk factors and anatomical sub-systems) combined with digital
patient data and visualisation tools would offer much needed help.
National and international guidelines provide evidence and
recommendations to assist clinicians in managing and treating
atherosclerosis [3, 4]. However, evidence is limited on identifying
individuals with subclinical atherosclerosis before a CVD event
occurs, especially since specialised diagnostic imaging is not part
of routine clinical practice [2]. The purpose of this Letter is to
present a simulation tool that integrates medical and physiological
data, to enable the development of predictive models to understand
the evolution and progression of atherosclerosis in individual
patients.
In this case, only biomechanical stimuli, patient-speciﬁc anatom-
ical data and measurements of individual LDL levels are included in
the modelling framework presented here, but the ultimate goal of
this work would be to integrate individual patient data at all relevant
levels of organisation, from the genome to the organism level, and
to include environmental factors to produce personalised predictive
models, with the objective of improving patient care. It is important
to highlight that the work presented here is the result of an extend-
able and expansible in-silico framework and could be adapted to13
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future knowledge and discoveries. It is also important to mention
that this in-silico framework and the model used as the basis of
this Letter do not present a ‘monolithic vision’ but are able to
adapt to future requirements instead. This is key, as this work
was initiated by the requirements of clinical practitioners at the
University College Hospital to begin to address some of the chal-
lenges they experience in their routine clinical practice.
This paper is divided as follows: Section 2 presents in a con-
densed way the key elements of the mathematical model used as
the basis of the in-silico workﬂow. Section 3 presents the simulation
workﬂow. An exemplar application of a patient-speciﬁc simulation
and its discussion will be presented in Section 4. Finally, Section 5
presents the conclusions of this work.
2. Mathematical model: The cornerstone of the technology
presented here is a mathematical model, described below; the
reader is also referred to [5] for completeness. The model
captures patient-speciﬁc and multi-scale aspects of the
atherogenesis process as brieﬂy explained in Section 1. The
essence of the model is encapsulated in Fig. 1.
2.1. Capturing and modelling the hemodynamics: Capturing
patient-speciﬁc hemodynamics is fundamental as atherosclerotic-
prone regions are linked with regions of low shear stress (see
Section 2.2). The calculation of physiological variables, such as
velocities and shear stress, will provide quantitative information
of the mechanical stimuli exerted by the blood ﬂow on the
endothelium and the endothelial cells. The hemodynamics of the
problem are calculated using the continuity (1) and Navier-Stokes
(2) as shown below
∂r
∂t
+∇ · (r U ) = 0 (1)
∂(r U )
∂t
+ ∇ · (r U × U ) = −∇p+∇ · t+ SM (2)
where, p and t are the pressure and stress tensor, respectively, [Pa]
and U is the ﬂow velocity (m/s). The term SM accounts for the
momentum of external forces to the system.
2.2. Correlation between endothelium behaviour and wall shear
stress – the endothelium as a porous wall: The endothelium is the
linen of blood vessels and the interface between the blood ﬂow
and the arterial wall (Fig. 1). Its behaviour is heavily inﬂuencedFigure 1 Representation of formation of foam cells and initiation of
atherogenesis
LDL particles enter arterial wall through endothelium; monocytes are
recruited and once in the wall, differentiate into macrophages. These
macrophages will capture LDL particles and the result will be foam cells
14
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in areas of altered hemodynamics, the endothelial cell does not
have a typical cobblestone shape [6] showing a more circular
shape instead. These more circular shaped endothelial cells show
an increased permeability, creating areas of higher
macromolecular migration inside the arterial wall. The model
uses a relationship between endothelial permeability and local
wall shear stress (WSS) based on the endothelial cell shape index
(SI) taken after experimental ﬁndings from [6]. SI is related to the
cellular shape and takes values from zero to one; that is, a circle
has a SI of one while a straight line has a SI of zero.
It was assumed that the value of normal WSS for an artery could
be calculated using the Poiseuille law for laminar ﬂow in a straight
pipe with the artery radius [7].
The relationship between WSS and SI is modelled by a continu-
ous function following [8]:
SI = −0.2435 · t
0.3537
t0
+ 0.4025 (3)
where t corresponds to the local WSS value and t0 is the normal
WSS.
2.3. LDL passage through the endothelium and
membrane-transport model: To model LDL passage through the
endothelium, a modiﬁed version of the Kedem Ketchalsky’s
equations for membrane transport was used [4]:
Jv = Lp Dpend − sdDP
( )
(4)
Js = Pi clum − cw,end
( ) Pe
ePe − 1+ Jv 1− s( )clum (5)
Pe = Jv(1− s)
Pi
(6)
where Jv is the volumetric ﬂux through the endothelium, Lp is the
hydraulic conductivity, Δpend is the pressure difference through
the endothelium, σd is the osmotic reﬂection coefﬁcient and ΔΠ
is the osmotic pressure (negligible, when compared with the
hydraulic pressure through the endothelium) [5].
The solute ﬂux, Js, can be divided into a convective component
entering the membrane and a diffusive component represented by
the ﬁrst and last terms of (5), respectively. Pi is the diffusive perme-
ability, Pe the modiﬁed Peclet number (6), cw,end the LDL concen-
tration in the arterial wall at the sub-endothelial layer and σ the
solvent drag coefﬁcient [5].
Three main pathways of macromolecule penetration were consid-
ered: leaky endothelial cell junctions; normal endothelial cell junc-
tions; and vesicular pathways [5]. The model considers that the bulk
of volume ﬂux through the endothelial membrane is given by:
Jv = Jv,lj+Jv,nj (7)
where Jv,lj is the ﬂux through leaky junctions and Jv,nj is the ﬂux
through normal junctions, as indicated in Fig. 2. The arterial wall
was modelled using an electrical analogy, where the ﬂow is
driven by a pressure difference and the resistance to the ﬂow enter-
ing the arterial wall is given by the endothelial layer
Jv =
Dpend
Rend
(8)
Here, ΔPend is the pressure difference through the endothelium,
taken from experimental values [9]. Rend is the resistance of the
endothelium and was calculated as the parallel sum of the resistanceHealthcare Technology Letters, pp. 13–18
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Figure 2 Schematic representation of biochemical processes of plaque
formation, key molecules and cells, endothelium junctions and intima +
mediaof leaky junctions and normal junctions [8]
1
Rend
= 1
Rlj
+ 1
Rnj
(9)
where Rlj is the resistance through the leaky junctions, calculated as
Rlj =
1
Lp,lj
(10)
and Rnj is the resistance through the normal junctions, calculated as
Rnj =
1
Lp,nj
(11)
To describe the LDL transport through normal junctions, normal
endothelial permeability (Pnj) and hydraulic conductivity (Lp,nj)
values were taken from experimental results (Table 1).
Following the three pores theory [8], solute ﬂux does not occur
through normal endothelial cell junctions, but it only occurs
through endothelial leaky cell junctions and vesicles
Js = Js,lj + Js,v (12)Table 1 LDL transport
Symbol Quantity Value
α LDL radius 11 nm
Alj leaky cell area 3.775 × 10
−12 m2
Dc LDL diffusion coefﬁcient in the
wall
8 × 10−13 m2/s
Dm monocytes diffusion coefﬁcient in
the wall
1 × 10−3 mm2/s
K Darcy’s permeability of arterial wall 2.9 × 10−18 m2
km foam cell formation constant 1 × 10
−6 s−1
Lp,nj hydraulic conductivity of normal
junctions
1.58 × 10−9 m(s·mm Hg)
Lp,lj hydraulic conductivity of single
leaky junctions
2.94 × 10−11 m/(s·mm Hg)
Pv diffusive permeability of vesicular
pathway
1.92 × 10−11 m/s
Ps,lj diffusive permeability of single
leaky junction
2.5 × 10−6 m/s
rw LDL degradation rate 3 × 10
−4 s−1
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Cwhere the solute ﬂux through the vesicular pathway (Js,v) is calcu-
lated as 10% of the solute ﬂux through the leaky junction pathway
(Js,lj) [4]. Having deﬁned the transport properties through both the
vesicular pathway and the normal junction pathway, the remaining
transport properties to be deﬁned are the ones describing the leaky
junction pathway.
Leaky cells have a high permeability to macromolecules such as
LDL, a factor that can be linked to the magnitude of WSS on the
endothelium. Experimental ﬁndings show that, in areas of low
WSS and high endothelial SI, the number of mitotic cells (MCs)
is increased [10], leading to a relationship between endothelial SI
and a number of MCs [8] that can be used to calculate the
number and the proportion of leaky cells over normal cells. This
would allows to determine the properties of the endothelium such
as hydraulic conductivity and diffusive permeability. The equations
are not shown here but see [4] for details. The values are shown in
Table 1.2.4. Modelling the atherosclerosis process inside the arterial wall –
a transport model: A monolayer approach was used, considering the
arterial intima and media with the internal elastic lamina and the
external elastic lamina as forming one single layer. The transport
of LDL inside the arterial wall was modelled in the direction
normal to the arterial lumen, via a convection-diffusion-reaction
equation [4]
dcw
dt
= −uw · ∇cw + DwDcw − rwcw (13)
The transmural velocity uw is calculated using Darcy’s law
uw =
K
mp
∇p (14)
where μp is the viscosity of plasma. The transport properties of the
arterial wall with respect to LDL are described by Darcy’s equation,
where the arterial wall has permeability K and a diffusion
coefﬁcient Dw. The last term of (13) is the degradation of the
LDL particles, with rw as the reaction coefﬁcient.
A relationship between the LDL concentration at the sub-
endothelial layer (cw,end) and the adventitia (cw,adv) of (cw,adv/
cw,end) = 0.005 (taken from [11]) was used as a boundary condition.
Owing to space limitations, see [5] for details on the oxydation
model and parameters used.
Once inside the arterial wall it is assumed that all monocytes
would differentiate into macrophages. Their transport has been
modelled with a diffusion-reaction equation
dMw
dt
= DmDMw − kmLoxMw (15)
Finally, the formation of foam cells (Fw) in the arterial wall is
calculated:
dFw
dt
= kmLoxMw (16)
where km is the kinetic constant for foam cells formation.
Foam cells are key in the process of remodelling of the arterial
wall and they were considered to be accumulating spheres follow-
ing close hexagonal packing. To simulate the initial process
leading to the plaque formation, it is proposed that, if the volume
covered by foam cells was larger than the initial arterial wall
portion considered, this would impose a lumen-side narrowing of
the arterial wall.15
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2.5. Description of the lumen-free approach: Concentration inside
the arterial blood was considered constant for both LDL and
monocytes, following a lumen-free approach. It is important to
note that the equations shown in this Section represent different
phenomena happening at different temporal and length scales.3. Multi-scale in-silico workﬂow for atherogenesis and the
patient-speciﬁc simulation of plaque formation: Since
atherosclerosis formation is a long-timescale process, we will
introduce for the purpose of this Letter what we will call an
‘atherosclerosis remodelling cycle’, which deﬁnes the whole
process of plaque formation and remodelling of the arterial wall.
This remodelling involves capturing patient-speciﬁc
hemodynamics for an individual at a time when the artery under
study was considered to be healthy, then the calculation of the
intima-media thickening via the set of equations deﬁned in
Section 2 and ﬁnally the remodelling of the lumen as a
consequence of atherosclerosis formation via estimation of the
number of foam cells. Fig. 3 illustrates the workﬂow of the
atherosclerosis remodelling cycle.
The core elements of the model are presented in this workﬂow
and these are based on the equations presented in Section 2. It is im-
portant to mention that this model is able to simulate, as a whole,
very long time scales. The simulation of this long-term process
has been rationalised by identifying diverse temporal scales
involved as follows: the ﬁrst and smallest time scale describes the
arterial wall model (accumulation of LDL and formation of foam
cells). This scale is of the order of hours/days. The second time
scale is used to update the endothelium model according to the
change of LDL concentration inside the arterial wall. This scale
is of the order of days/weeks. The third time scale is the time
length of the entire atherosclerosis remodelling cycle. This scale
is of the order of months or years.Figure 3 Atherosclerosis remodelling cycle
There is a feedback loop between the remodelling of the arterial wall and the
calculation of the permeability of the endothelium, which will be affected
becoming more porous as atherosclerosis progresses, facilitating the
penetration of LDL particles and increasing the number of foam cells.
This process is captured in time
16
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steady-state, hence temporal changes in haemodynamic variables
are not captured with the current setup. A new haemodynamic
simulation was run (and new values of blood ﬂow-related variables
calculated) when the growth calculated by the model described in
Section 2 was large enough (of the order of μm) to be captured in
3D simulation; meaning, there were small but quantiﬁable differ-
ences in ﬂow characteristics between the ‘previous’ geometry and
the ‘new’, calculated one. Once the WSS patterns and values
change, the permeability of the endothelium changes, increasing
the penetration of macromolecules into the wall creating a feedback
loop (see Fig. 3).
This workﬂow was developed with the aim of producing a com-
prehensive framework for the multi-scale modelling of atheroscler-
osis. Different computer tools/software were used: the
hemodynamics in the arterial lumen were modelled in Ansys CfX
v.14. The arterial endothelium and arterial wall were modelled
and implemented in Matlab. The meshing was done in Ansys
ICEM CFD. The simulation workﬂow has been entirely parallelised
and we would like to think it presents a valid alternative to the
patient-speciﬁc modelling and simulation of plaque, as it is sepa-
rated into individual components and is able to harness the power
of parallel computing to perform calculations that would be other-
wise intractable, in order to simulate long periods of time.4. Exemplar application of the simulation-based technology–
a personalised model of atherogenesis: Patient-speciﬁc data was
obtained from the vascular clinic at UCLH. Appropriate patient
consent for patient data use was obtained by the managing
clinician. The segmented patent lumen geometry of the left
common femoral artery (CFA), with the deep femoral artery
(DFA) and the superﬁcial femoral artery (SFA) from one of the
patients in the study is shown in Fig. 4.
The inlet area of the left CFA is A0, leftCFA = 7.84 × 10
−5 m2, with
a surface area of the inlet added pipe of Ainlet = 6.09 × 10
−5 m2. The
mean velocity of the left CFA, as extracted from Doppler
Echocardiography recordings, was U0 = 0.207 m/s. Blood was
modelled as a steady, homogeneous, incompressible ﬂuid with con-
stant viscosity. Blood properties were kept constant with a viscosity
of μ = 0.0035 Pa s and a density of ρ = 1050 kg/m3 [7]. Flow con-
tinuity was applied to calculate the mean velocity at the inlet of
the pipe. The endothelial response to the local WSS values wasFigure 4 Geometry of model of left CFA, with DFA and SFA and plaque
scoring obtained from CT scans
Atherosclerotic plaques are segmented in contrast colour (light blue) from
the patent lumen (purple): detected plaques are numbered. Note that these
are two views of the same arteries in order to show the three plaques detected
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Figure 6 Mesh deformation contour plot of left CFA with DFA and SFA
Plaques occurrence was modelled solely in left CFA (in red); area of mesh
displacement indicates plaque formationtuned with the calculated Poiseuille law WSS for the left CFA. The
Poiseuille WSS was calculated to be t0 = 0.657 Pa.
Multi-slice computed tomography (MSCT) plaque scoring was
carried out with the assistance of a clinician on the arterial
segment of the left CFA with the DFA and the SFA, as shown in
Fig. 4. The lesions identiﬁed were in the left CFA and this is the
segment that will be subject to remodelling during the simulation.
Owing to the small extent of calciﬁcation detectable in the MSCT
images, there is uncertainty in the plaques detected and their seg-
mentation. The ﬂuid domain of the left CFA, with the DFA and
the SFA, was meshed with Ansys ICEM CFD. The mesh created
was a 1.1 million elements Delaunay unstructured mesh with pris-
matic layers at the wall boundary.
To obtain the characteristics of the lumen geometry before
disease occurrence, the plaques detected were segmented together
with the free lumen. An artery-speciﬁc WSS contour plot is
shown in Fig. 5, obtained by re-scaling the global WSS contour
plot, by setting the maximum WSS as the calculated Poiseuille
WSS value for a pipe with the same cross sectional dimension
and mean ﬂow velocity of the artery considered.
In this exemplar, two out of the three plaques (1 and 3 in Fig. 4)
were shown by the computational model, either in the normalised
WSS plot (Fig. 5) or the mesh deformation plot (Fig. 6). Plaque
2 was not developed by the model or shown by the normalised
WSS contour plot in the location identiﬁed by the ﬁgure showing
plaque scoring (Fig. 4); however, there is a region of low WSS
above plaque 1, which could correspond to plaque 2. It is important
to mention that from in-vivo observations, it has emerged that the
majority of plaques would develop in areas close to arterial bifurca-
tions and this has been already reported numerous times in the lit-
erature [12]. It could be, therefore, necessary to segment every
different branch, even the minor ones, to accurately model the
artery hemodynamics. This fact could affect the generation of
plaque 2 by the model.
Additionally, we are using imaging data available routinely
through the National Health Service, which in essence means that
the model is dealing with data that was not acquired for research
purposes. In the case of the exemplar shown here, there is a non-
negligible inﬂuence of the quality of the images and the successive
errors that might have been produced during their processing.
The development of the plaque, shown in Fig. 6, has a simulated
time of 20 years and 9 months. Careful consideration must be given
to the meaning of the time indication of atherosclerosis formation in
this simulation. The anatomical features were extracted from anFigure 5 Re-scaled WSS contour plot of left CFA
Plot maximumWSS detectable is Poiseuille WSS for left CFA t0 = 0.6572 Pa
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Cadult patient and it was assumed that the arterial tree of the
patient would reach full anatomical development in 18 years,
without presenting any atherosclerosis formation and with arterial
lumen and an arterial wall fully patent. This is, however, just an in-
dication of the capabilities of the model to simulate long periods of
time. It is only fair to mention that the hypotheses and the model
proposed account for processes that happen during the early
stages of plaque formation. Other assumptions and mechanisms
for the modelling of later stages of the plaque will be considered
in future work.
Although the ﬂow was simulated using a rigid wall approxima-
tion, the assumption of a rigid wall is not expected to inﬂuence
the results in this case as a steady state simulation is performed [13].
There is obviously room for improvement in the development of
this technology. First of all, it is important to mention that the
model, as it is, is not intended to be used for the analysis of
plaque rupture. Investigations of the two inter-connected processes
(plaque growth and rupture) have been intensive in the past several
decades with excellent work available in the literature. Second, it is
important to highlight that this is a parsimonious model of athero-
sclerotic plaque formation. The model captures the fundamental
biological hypotheses of plaque formation available in the litera-
ture, but it would require the incorporation of many other mechan-
isms deemed important for the formation of atherosclerosis in
individuals. For example, speciﬁc genotypes and gene expression
(apoE for example) are not considered. It would also be interesting
to explore the contribution of other well-known risk factors of ath-
erosclerosis, such as high blood pressure and smoking. One of the
challenges in all mechanistic models lies in the correct identiﬁcation
of the relevant or appropriate mechanisms that will result in the
expected outcome. This is not an easy obstacle to overcome as
we are only able to model current knowledge. However, this
model does work as an integrator or hypotheses tester. The fact
that this model can efﬁciently simulate very long time scales (simu-
lating years of growth) in a few days is, per se, an important asset as
the atherosclerosis process can then be validated against in-vivo
data, either in animals or humans (using clinical data if available).
Another aspect that requires further improvement is that the model
is very sensitive to segmentation and meshing. It is rather difﬁcult to
obtain high quality images for all the patients as we are working
with data that is routinely available in vascular clinics. Images
that are limited in their quality negatively affect the potential of
the model and the routine-use of the framework.
To partially overcome these obstacles, a study on a population of
patients (with follow-up) at the University College Hospital will be
undertaken. This will allow us to collect relevant data to reﬁne the
model, to test it, to validate it numerically but also, and very17
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importantly, to validate it in the clinic. The objective is that this
study will not only help to develop the technology further but
will also help to break the barriers of adoption of this type of tech-
nologies in routine clinical practice in the vascular service at
UCLH.
5. Conclusion: The development of personalised in-silico
technologies for better healthcare is key to address the many
constraints that National Health systems face today. In this Letter,
we presented an in-silico framework to comprehend and manage
atherosclerotic plaque progression in individual patients. The
fundamental idea behind this technology is that, by understanding
the underlying biology and physiology through the encapsulation
of this knowledge into mathematical models, we will be able to
create rich and persuasive predictive technologies for healthcare.
The model-based technology described in this Letter presents an
extensible model that can help clinicians to test hypotheses to
understand plaque progression in individual patients in order to
make more informed decisions about timescales, potential
interventions, available treatments and, potentially, lifestyle
changes. In the near future, we will work even more closely with
clinical colleagues in the vascular service at UCLH to ensure that
our research contributes to the broader objectives of the vascular
clinic in the hospital and eventually beyond. The ultimate goal is
that this framework could become part of routine diagnosis or
routine care.
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